Epizyme Inc (NASDAQ:EPZM) posted its quarterly earnings data on Monday. The biopharmaceutical company reported ($0.56) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.63) by $0.07. Epizyme had a negative net margin of 1,205.01% and a negative return on equity of 41.56%.

Shares of Epizyme (NASDAQ:EPZM) traded up 6.871% during trading on Friday, hitting $18.275. The company had a trading volume of 198,317 shares. The company’s 50 day moving average is $16.04 and its 200 day moving average is $13.24. The firm’s market capitalization is $1.07 billion. Epizyme has a 1-year low of $7.02 and a 1-year high of $18.50.

Earnings History for Epizyme (NASDAQ:EPZM)

In related news, insider Robert A. Copeland sold 5,000 shares of the firm’s stock in a transaction dated Tuesday, May 2nd. The shares were sold at an average price of $17.44, for a total value of $87,200.00. Following the completion of the sale, the insider now owns 36,538 shares in the company, valued at $637,222.72. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CFO Andrew E. Singer sold 2,013 shares of the firm’s stock in a transaction dated Friday, March 31st. The shares were sold at an average price of $17.09, for a total transaction of $34,402.17. Following the completion of the sale, the chief financial officer now owns 36,175 shares of the company’s stock, valued at approximately $618,230.75. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 12,013 shares of company stock worth $203,402. Corporate insiders own 25.40% of the company’s stock.

Several large investors have recently bought and sold shares of the stock. Principal Financial Group Inc. boosted its position in shares of Epizyme by 0.5% in the first quarter. Principal Financial Group Inc. now owns 94,173 shares of the biopharmaceutical company’s stock worth $1,615,000 after buying an additional 515 shares during the period. Legal & General Group Plc boosted its position in shares of Epizyme by 8.9% in the first quarter. Legal & General Group Plc now owns 9,684 shares of the biopharmaceutical company’s stock worth $165,000 after buying an additional 795 shares during the period. American International Group Inc. boosted its position in shares of Epizyme by 7.1% in the first quarter. American International Group Inc. now owns 24,779 shares of the biopharmaceutical company’s stock worth $425,000 after buying an additional 1,638 shares during the period. Teachers Advisors LLC boosted its position in shares of Epizyme by 3.1% in the first quarter. Teachers Advisors LLC now owns 69,922 shares of the biopharmaceutical company’s stock worth $1,199,000 after buying an additional 2,093 shares during the period. Finally, Metropolitan Life Insurance Co. NY boosted its position in shares of Epizyme by 11.9% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 30,680 shares of the biopharmaceutical company’s stock worth $371,000 after buying an additional 3,269 shares during the period. Institutional investors own 79.98% of the company’s stock.

A number of research analysts have recently commented on EPZM shares. HC Wainwright reissued a “buy” rating on shares of Epizyme in a report on Friday. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $19.00 price objective (down previously from $26.00) on shares of Epizyme in a research note on Saturday, March 11th. Wedbush reaffirmed an “outperform” rating and issued a $24.00 price objective on shares of Epizyme in a research note on Thursday. Zacks Investment Research raised Epizyme from a “hold” rating to a “buy” rating and set a $18.00 price objective for the company in a research note on Tuesday. Finally, Cann reissued a “buy” rating and set a $26.00 target price on shares of Epizyme in a research report on Tuesday, April 25th. Eleven analysts have rated the stock with a buy rating, The stock currently has a consensus rating of “Buy” and a consensus price target of $24.88.

TRADEMARK VIOLATION WARNING: “Epizyme Inc (EPZM) Releases Earnings Results, Beats Estimates By $0.07 EPS” was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece of content on another publication, it was stolen and republished in violation of United States & international trademark & copyright legislation. The legal version of this piece of content can be read at https://www.thecerbatgem.com/2017/05/19/epizyme-inc-epzm-announces-quarterly-earnings-results-updated.html.

About Epizyme

Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs).

5 Day Chart for NASDAQ:EPZM

Receive News & Stock Ratings for Epizyme Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme Inc and related stocks with our FREE daily email newsletter.